If confirmed by future systematic validation studies, this WES/WGS–based identification strategy of RFC1 repeat expansions might be applicable as a first-line screening strategy for existing WES/WGS datasets of unsolved ataxia cohorts, thus saving resources and allowing accelerated identification of still unidentified patients with RFC1. This evidence concerns the gene RFC1 and Ataxia.